Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

The conversation is about someone switching from Minoxidil and Finasteride to Redensyl, Procapil, and Capixyl serums due to anxiety over potential side effects, and they are inquiring about others' regrowth experiences with these serums. Some doctors in India have prescribed these serums, and the person knows others who are satisfied with the results.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.

A user is considering a $5,295 one-year hair loss program from HairClub/Bosley, which includes treatments like finasteride, minoxidil, and a DNA test to personalize treatment. Opinions are mixed, with some suggesting cheaper alternatives like standard medications and questioning the value of the program.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

A user is seeking information on clinics in Toronto offering dutasteride mesotherapy as an alternative to oral dutasteride while trying to conceive. They are looking for recommendations and information.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

The conversation is about finding clascoterone 5% or other effective anti-androgens for hair loss in the UK, with openness to purchasing from outside the UK. A suggestion was made to visit Dublin, where research on the treatment is ongoing.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The user plans to switch from finasteride to dutasteride for hair loss and is treating seborrheic dermatitis with Nizoral and Stanhome Balance shampoos. They are considering trying Vichy Psolution shampoo and Ciclopirox, and are dealing with challenges due to Vietnam's humidity.

The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.

Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.

Clascoterone stopped shedding for one user, but no visual regrowth was noted after 3 months. The user experienced side effects with finasteride, dutasteride, and RU58841, but not with oral minoxidil and clascoterone.

The conversation discusses the effectiveness of the AutumnValley Anti-hair Loss Complex Pack for hair growth and hair loss prevention. The original poster is considering adding it to their regimen, which already includes Minoxidil, finasteride, and RU58841.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The user is exploring topical treatments AHK-CU and GHK-CU for hair loss, avoiding Minoxidil and prescription medications. They believe their hair loss is not genetic but caused by Accutane, and are considering products like Neurogan and Bloom by Fleur.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

The user noticed thicker hair at their hairline after using a skincare serum containing GHK-CU, despite using pyrilutamide for hair loss without success. They plan to apply the serum more broadly to see if it improves hair growth.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

Dr. Tsuji's stem cell hair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.